BioNTech SE - Crunchbase Company Profile & Funding

Q: Where is BioNTech SE's headquarters?

BioNTech SE is located in Mainz, Rheinland-Pfalz, Germany.

Overview

BioNTech SE

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Events

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

+2 more milestones

See more interactive data and historical milestones on desktop for the best experience

About BioNTech SE

CB Rank

228557

At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized.

Founded

obfuscation

Private

Mainz, Rheinland-Pfalz, Germany

1001-5000

biontech.de/

Health Care

Key People

James Ryan: Chief Legal Officer
Past Role: BioNTech SE, General Counsel & Senior Vice President Legal & IP
Kylie Jimenez: Chief People Officer
Past Role: Georg Fischer, Global Chief Human Resources Officer

Details

Legal Name

BioNTech SE

Operating Status

Active

Company Type

For Profit

Predictions & Insights

Growth Insight

See this Growth Insight

BioNTech SE is

Lorem

to be growing

Top Contributing Factors

Headcount Reduction

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Key Employee Changes

Products & Services

mRNA Therapeutics

BioNTech uses messenger RNA (mRNA) to deliver genetic information to cells for producing proteins for therapeutic purposes, developing a broad portfolio of immunotherapies and exploring new formulations for vaccines against cancer and infectious diseases.

Programmable Cell Therapies

BioNTech develops novel cell therapies where patients' T-cells are modified to target cancer-specific antigens. This includes platforms for treating solid tumors with CAR-T cells and TCR programs, and combining mRNA FixVac platform with CAR-T product candidates to enhance CAR-T cells' durability in vivo.

Research & Development

BioNTech SE is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...